Hypertension and Anxiety Disorders Comorbidity
Conditions
Interventions
(Study 1) Case Group:None
(Study 1) Control Group:None
(Study 3) Mild-moderate anxiety intervention group:Received standardized CBT-H dual-cardiac collaborative digital intervention, intervention duration 2 weeks
(Study 3) Severe anxiety ntervention group:Received pharmacotherapy combined with intensive CBT-H intervention, intervention duration 2 weeks
(Study 4) Intervention Group Level 1 (Mild-Moderate Anxiety):Standardized CBT-H dual-cardiac collaborative digital intervention, intervention duration 6 weeks
(Study 4) Intervention Group Level 2 (Severe Anxiety/Non-Response):Psychiatric medication combined with intensive CBT-H intervention, intervention duration 6 weeks
(Study 4) Control Group:Routine cardiology antihypertensive treatment and health guidance without additional digital intervention
Sponsors
The First Medical Center, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria Applicable to all subjects: 1. Aged between 18 and 60 years old. 2. Meet the diagnostic criteria for essential hypertension specified in the Chinese Guidelines for the Prevention and Treatment of Hypertension (2018 Revised Edition). 3. Have normal cognitive function, basic reading and writing abilities, and be proficient in using smartphone applications (APPs). 4. Voluntarily participate in this study and sign the written informed consent form.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria will be excluded: 1. Patients with secondary hypertension, hypertensive emergency or hypertensive urgency. 2. Patients with severe dysfunction of vital organs (e.g., NYHA class III or higher heart failure, Child-Pugh class C liver function, end-stage renal disease on dialysis) or active malignant tumor. 3. Patients with severe cerebrovascular or neurological diseases, including but not limited to symptomatic cerebral atherosclerosis, history of stroke, dementia, Parkinson's disease, and intracranial space-occupying lesions. 4. Patients with other severe mental disorders (e.g., major depressive episode, schizophrenia, bipolar affective disorder, obsessive-compulsive disorder [OCD]) or at high suicide risk. 5. Pregnant or lactating women. 6. Any condition that may significantly interfere with study participation or follow-up, such as illiteracy, inability to perform activities of daily living independently, planned relocation out of the study area, or concurrent participation in other interventional clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Rating Scale (HAMA) Score;Adrenal Computed Tomography (CT) Imaging Indicators; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate variability (HRV) indicators (SDNN, LF/HF ratio);Office systolic blood pressure/diastolic blood pressure;12-Item Short Form Health Survey (SF-12) Physical Component Summary (PCS) Score;Serum Cortisol Level;Serum C-Reactive Protein (CRP) Level;Serum Interleukin-6 (IL-6) Level;Serum Renin/Aldosterone Ratio;Serum 25-Hydroxyvitamin D Level;Salivary Cortisol Level;Resting Electroencephalogram (EEG) Indicators;Mini International Neuropsychiatric Interview (MINI-5) Suicide Risk Score;Body Mass Index (BMI);Level of Social Support;Exposure to Recent Negative Life Events;Medication Adherence Score;Satisfaction Score with Digital Intervention Platform;Intervention Completion Rate; | — |
Countries
China
Contacts
Public ContactRonghuan Jiang
The First Medical Center, Chinese PLA General Hospital
Outcome results
None listed